Review of Sorafenib data at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 13 to May 17, 2005

Tuesday, May 17, 2005:
Investor Conference Call ASCO Review 2005

The audio recording of this event is no longer available.

Fact Sheets and Background Information
Sorafenib Clinical Program OverviewDownload (PDF, 120 KB) collect
Sorafenib Fact SheetDownload (PDF, 139 KB) collect
Renal Cell Carcinoma Fact SheetDownload (PDF, 114 KB) collect
Hepatocellular Carcinoma Fact SheetDownload (PDF, 138 KB) collect
Melanoma Fact SheetDownload (PDF, 119 KB) collect
Sorafenib at ASCO 2005Download (PDF, 119 KB) collect

Abstracts and Oral Presentations on Sorafenib at ASCO 2005

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: LBA4510)

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: 4544 )

A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) ( Abstract No: 5566)

Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients ( Abstract No: 7508)

Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma ( Abstract No: 3037)

A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) ( Abstract No: 3067)

Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma ( Abstract No: 3005)

Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: A prospective study ( Abstract No: 3069)

Useful Links:

ASCO Homepage:

Clinical trials information:

American Cancer Society:

Information on renal cell cancer:

Information on liver cancer:

Information on melanoma:

Information on cancer incidence, prevalence and mortality (GLOBOCAN):

Last updated: January 13, 2014 Copyright © Bayer AG